Izna Ali

No ORCID on file · 1 paper in corpus
other 2023
Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome
F&S reports ·doi:10.1016/j.xfre.2023.02.007

OBJECTIVE: Evaluate the efficacy and safety of elagolix, a GnRH antagonist, to treat polycystic ovarian syndrome (PCOS). DESIGN: A phase 2, multicenter, double-blind, randomized, placebo-controlled trial. SETTING: Outpatient and academic …